论文部分内容阅读
目的:探讨微生态制剂对肝硬化患者肠源性内毒素血症的治疗作用。方法:将58例肝硬化具有肠源性内毒素血症的患者分为观察组和对照组,两组间在性别、年龄、病程、临床特点及血清内毒素水平方面无统计学差异。观察组在对照组的基础上加用微生态制剂整肠生治疗,治疗2周后再次检测两组的血清内毒素水平,并进行统计学分析。结果:治疗前两组血清内毒素水平分别为(69.33±27.12)pg/ml和(67.79±26.07)pg/ml(P>0.05),其间无统计学差异;治疗后两组血清内毒素水平分别为(32.04±14.76)pg/ml和(58.97±25.11)pg/ml(P<0.05),差异有统计学意义。结论:微生态制剂对肝硬化患者肠源性内毒素血症有治疗作用。
Objective: To explore the therapeutic effect of probiotics on enterogenous endotoxemia in cirrhotic patients. Methods: 58 cases of patients with liver cirrhosis with enterogenous endotoxemia were divided into observation group and control group. There was no significant difference in gender, age, course of disease, clinical features and serum endotoxin between the two groups. The observation group was treated with probiotics on the basis of the control group. After two weeks of treatment, the levels of serum endotoxin in both groups were measured again and statistically analyzed. Results: The levels of endotoxin in the two groups before treatment were (69.33 ± 27.12) pg / ml and (67.79 ± 26.07) pg / ml, respectively. There was no significant difference between the two groups (32.04 ± 14.76) pg / ml and (58.97 ± 25.11) pg / ml respectively (P <0.05), the difference was statistically significant. Conclusion: The probiotics have a therapeutic effect on enterogenous endotoxemia in cirrhotic patients.